Unione Europea - italiano - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - agenti antineoplastici - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Unione Europea - italiano - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - agenti antineoplastici - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinoma, polmone non a piccole cellule - agenti antineoplastici - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Unione Europea - italiano - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Unione Europea - italiano - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - elotuzumab - mieloma multiplo - agenti antineoplastici - empliciti è indicato in combinazione con lenalidomide e desametasone per il trattamento del mieloma multiplo in pazienti adulti che hanno ricevuto almeno una precedente terapia (vedere sezioni 4. 2 e 5.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

amgen switzerland ag - blinatumomabum - polvere per concentrato per soluzione per infusione - praeparatio cryodesiccata: blinatumomabum 38.5 µg, acidum citricum monohydricum, trehalosum dihydricum, lysini hydrochloridum, polysorbatum 80, natrii hydroxidum, pro vitro corresp. natrium 1.5 mg. solvens: acidum citricum monohydricum, lysini hydrochloridum, polysorbatum 80, natrii hydroxidum, aqua ad iniectabile q.s. ad solutionem pro 10 ml corresp. natrium 18.35 mg. - onkologikum - biotechnologika

Unione Europea - italiano - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - linfoma a cellule b - agenti antineoplastici - polivy in combinazione con bendamustine e rituximab è indicato per il trattamento di pazienti adulti con recidivato/refrattario diffuso a grandi cellule b (dlbcl), che non sono candidati per il trapianto di cellule staminali ematopoietiche. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - polatuzumabum vedotinum - polvere per concentrato per soluzione per infusione - polatuzumabum vedotinum 140 mg, acidum succinicum, natrii hydroxidum corresp. natrium 2.18 mg, saccharum, polysorbatum 20, pro vitro. - onkologikum - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - polatuzumabum vedotinum - polvere per concentrato per soluzione per infusione - polatuzumabum vedotinum 30 mg, acidum succinicum, natrii hydroxidum corresp. natrium 0.47 mg, saccharum, polysorbatum 20, pro vitro. - onkologikum - biotechnologika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

kyowa kirin sàrl - mogamulizumabum - concentrato per soluzione per infusione - mogamulizumabum 20 mg, acidum citricum monohydricum, glycinum, polysorbatum 80, natrii hydroxidum q.s. ad ph, acidum hydrochloricum q.s. ad ph, aqua ad iniectabile ad solutionem pro 5 ml. - poteligeo ist indiziert für die behandlung von erwachsenen patienten mit rezidivierter oder refraktärer mycosis fungoides (mf) oder sézary-syndrome (ss), welche mindestens eine vorherige therapie erhalten haben (siehe abschnitt «klinische wirksamkeit»). - biotechnologika